translocations or amplifications on top of the genomic alterations currently present in the original CLL, but lack the frequent mutations noticed in Major DLBCL indicating they may correspond to another biological class.gene in people relapsing following remedy Along with the BCL2 antagonist venetoclax. sixty six Resistance to those brokers has lon